Information For Healthcare Professionals

Notice: Mpox illness, including severe infections, continue to occur across the United States. CDC urges clinicians to consider mpox when lesions consistent with mpox are observed in a patient, even if an alternate etiology (e.g., herpes simplex virus, syphilis) is considered more likely. Consult public health authorities for access to mpox therapeutics when appropriate. Treatment with tecovirimat can be considered via the NIH sponsored STOMP trial. Tecovirimat use under the expanded access Investigational New Drug protocol must be for patients who meet eligibility criteria and per the recommended dosing.

For people 18 years and older with sexual risk factors for mpox who have not been diagnosed with mpox or have not already received 2 doses of the JYNNEOS vaccine, CDC recommends the administration of a 2-dose JYNNEOS series separated by at least 28 days. Administration of additional vaccine doses (more than 2 doses) is currently not recommended. JYNNEOS is available for use for children and adolescents under 18 years determined to be at high risk for mpox under the Emergency Use Authorization (EUA) issued by the US Food and Drug Administration.

Caring for Patients
Key Characteristics for Identifying Mpox

CDC urges healthcare providers in the U.S. to be alert for patients who have rash illnesses consistent with mpox.

Clinical Recognition
Prevent and Control Mpox
Vaccine Information

When properly administered before an exposure, vaccines are effective at protecting people against mpox.